People

LiGHT Trial Co-Coordinating Centres

Address

Moorfields Eye Hospital
2nd Floor Research and Development
162 City Road
EC1V 2PD

Contacts

Chief Investigator

Gus Gazzard
g.gazzard@nhs.net

Research Manager

Amanda Davis
amanda.davis5@nhs.net
020 7566 2823

Lead Trial Optometrist

Neil Nathwani
n.nathwani@nhs.net
020 7566 2817

Data Officer

Taniya Chowdhury
taniya.chowdhury@nhs.net
020 7566 2835

About the team

The trial team is a group of ophthalmologists and researchers working at Moorfields Eye Hospital. The chief investigator is Mr Gus Gazzard and the trial team comprises Neil Nathwani (trial optometrist) and Amanda Davis (trial manager).

The LiGHT trial has been funded by the National Institute for Health Research (NIHR), established in 2006 by the Department of Health. The NIHR provides the framework through which the research staff and research infrastructure of the NHS in England is positioned, maintained and managed as a national research facility. The NIHR provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training. Its aim is to support outstanding individuals (both leaders and collaborators), working in world-class facilities (both NHS and university), conducting leading-edge research focused on the needs of patients. To find out more, please visit www.nihr.ac.uk.

The trial team is also working with the PRIMENT Clinical Trials Unit (CTU), a partnership between the UCL Research Department of Primary Care & Population Health, Mental Health Sciences Unit and the Department of Statistical Science. PRIMENT CTU collaborates with internal and external researchers to develop and/or evaluate complex interventions in primary care, psychiatric and community settings. The unit has a particular focus on mental health and behavioural change interventions. PRIMENT is a UK Clinical Research Collaboration (UKCRC) registered clinical trials unit. UKCRC registration recognises the CTU's strengths in conducting major trials and other large, well-designed studies.